copyright use disorder (CUD) is a major public health challenge with a high relapse rate and lack of effective pharmacotherapies; therefore. there is a substantial need to identify novel medications to treat this epidemic. Since the advent of glucagon-like peptide-1 (GLP-1) receptors (GLP-1Rs) agonists (GLP-1RAs). their potential has been extensively explored and expanded. https://www.parisnaturalfoodes.shop/product-category/clo-lightly-lem/